VEEV Q1 Deep Dive: AI-Driven Product Expansion and New Platform Initiatives Highlight Quarter

Veeva just announced CRM migration wins with Teva and Merck KGaA. Big names, big deals, big press release energy.

Here's what that actually tells you: even global pharma giants are still switching CRMs. Companies with armies of IT staff, dedicated implementation teams, and nine-figure budgets are still mid-migration, still betting on a platform that fits better than the last one.

That's not a knock on Veeva. It's a reminder that CRM migration never really stops for anyone — it's an ongoing bet that this time the platform will actually match how the business runs.

If you're a mid-market ops leader, that story probably feels familiar. You've been through at least one of these already. The platform promised flexibility. The consultants promised speed. The timeline slipped. The team complained. And six months later you were customizing around the same basic problems, just with a different logo on the login screen.

The lesson from these enterprise wins isn't that you need a bigger platform or a fancier AI layer. It's that switching CRMs is expensive at every company size — which means the cost of getting it wrong again isn't just money, it's credibility.

The companies that stop cycling through platforms are the ones that stopped asking "which CRM is best" and started asking "which one actually fits our workflows without a consultant in the room."

#CRM #SalesOps #MidMarket #CRMStrategy #OperationsLeadership

Original Source

CRM migration wins: Veeva secured notable customer wins in CRM, including global agreements with Teva and Merck KGaA, and reported a win rate ...